

---

**HOUSE COMMITTEE AMENDMENTS**

2019 Regular Session

Amendments proposed by House Committee on Insurance to Original House Bill No. 370  
by Representative Stokes

---

1 AMENDMENT NO. 1

2 On page 1, at the beginning of line 17, change "D." to "D.(1)"

3 AMENDMENT NO. 2

4 On page 2, at the beginning of line 1, change "(1)" to "(a)"

5 AMENDMENT NO. 3

6 On page 2, at the beginning of line 3, change "(2)" to "(b)"

7 AMENDMENT NO. 4

8 On page 2, between lines 3 and 4 insert the following:

9 "(2) The provisions of Paragraph (1) of this Subsection shall  
10 not apply if the health coverage plan's preferred drug or drug regimen  
11 is considered an equivalent option for therapy or a higher ranked  
12 evidence-based option for therapy as compared to the prescribed drug  
13 or drug regimen according to the National Comprehensive Cancer  
14 Network Guidelines Categories of Evidence and Consensus or the  
15 Categories of Preference.

16 (3) For drugs prescribed for associated conditions as defined  
17 in Subsection E of this Section, the treating physician shall inform  
18 the health coverage plan that the condition to be treated is associated  
19 with stage-four advanced, metastatic cancer when requesting  
20 authorization."

21 AMENDMENT NO. 5

22 On page 2, between lines 11 and 12, insert the following:

23 "(3) As used in this Section, "associated conditions" means the symptoms or side effects  
24 associated with stage-four advanced, metastatic cancer or its treatment."